Exon

New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse

Retrieved on: 
söndag, juni 2, 2024
Science, Biotechnology, Research, Surgery, Oncology, Health, Genetics, Clinical Trials, Breast cancer, ASCO, Institute of Cancer Research, NHS foundation trust, Patient, Cell, Ultra, Cancer, The Institute, Exon, Society, DNA, Chief Justice of Hungary, Molecular oncology, MRD, Genome, Sequence, Woman, WES, Recurrence, Risk, Disease, Blood, ICR, Gene, Breast, Diagnosis, Whole genome sequencing, Weapon, Survival, Neoplasm, WGS, Medical imaging

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Key Points: 
  • A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.
  • Blood samples from 78 patients with different types of early breast cancer (23 with triple negative breast cancer, 35 with HER2+ breast cancer, 18 with hormone receptor+ breast cancer and two with an unknown subtype) were screened for ctDNA.
  • The median lead time to clinical relapse in this group of patients was 15 months, an increase of over three months, compared with other ctDNA tests in all types of breast cancer.
  • The study shows the importance and promise of using an ultra-sensitive MRD test like NeXT Personal to detect the earliest traces of breast cancer recurrence, and more optimally guide management of breast cancer patients.”

IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST

Retrieved on: 
måndag, juni 3, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ASCO, RECIST, Vomiting, Patient, Fatigue, Mutation, Diarrhea, Strategist, Annual general meeting, KIT, Data, Exon, Safety, Hypertension, Society, UZ Leuven, Appetite, DNA, Circulating tumor DNA, Infrared spectroscopy correlation table, First grade, Death, TKI, Dysgeusia, BID, Neoplasm, GIST, PRS, Nausea, Pharmaceutical industry

These data will be highlighted today in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • These data will be highlighted today in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “There is a significant unmet medical need for next-generation therapies for GIST patients.
  • 74% of patients remained on study treatment, and the median duration of treatment was 16 weeks as of the data cut-off.
  • “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx.

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Genetics, Liver disease, Coronary artery disease, Research, N-Acetylgalactosamine, Weight loss, Doctor of Philosophy, Webcast, SVP, DSM-IV codes, CSO, Biomarker, Drug discovery, AATD, RNA editing, Activin and inhibin, Facial muscles, Pharmacokinetics, LNP, SAD, GSK, Serum, Duchenne muscular dystrophy, HTT, Cerebrospinal fluid, MASH, Weight, Safety, Health, RNA, Obesity, Human, Therapy, HD, Central nervous system, Clinical trial, ED50, Small RNA, Stanford University, Lof, Genomics, Exon, Science, Senior, Patient, Cardiovascular disease, MBA, PD, Lipolysis, Q&A, Pharmaceutical industry

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.
  • Net loss was $31.6 million for the first quarter of 2024, as compared to $27.4 million for the first quarter of 2023.
  • ET to review the first quarter 2024 financial results and pipeline updates.

Arbor Biotechnologies Announces Acquisition of Serendipity

Retrieved on: 
onsdag, maj 8, 2024
Harvard University, Exon, CRISPR, Broad Institute, Gene editing, RNA, Acquisition, Gene, MIT

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.
  • Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard.
  • The innovative assets, which include Fanzor-based, IsrB-based, and additional undisclosed programmable editing technologies, complement and expand Arbor’s existing editing capabilities.
  • Our primary focus is on developing novel therapies for indications in the liver and CNS with significant unmet need while partnering in other areas,” said Devyn Smith, Ph.D., Chief Executive Officer of Arbor Biotechnologies.

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
onsdag, mars 6, 2024
Therapy, Facial muscles, Pharmacology, Central nervous system, Research, GSK, MD, Liver disease, Dystrophin, Obesity, Cerebrospinal fluid, N-Acetylgalactosamine, HD, Weight loss, DMD, Duchenne muscular dystrophy, Lof, Exercise, Lipolysis, Exon, MBA, Conference, Wave, Activin and inhibin, AATD, Health, Safety, Biomarker, RNA, Greenshoe, Genetics, Pharmacokinetics, Webcast, Patient, Clinical trial, HTT, Q&A, Small RNA, Serum, Episcopal conference, Human, Coronary artery disease, Pharmaceutical industry

In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.

Key Points: 
  • In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.
  • Revenue was $29.1 million for the fourth quarter of 2023 as compared to $1.2 million in the prior year quarter.
  • Net loss was $16.3 million for the fourth quarter of 2023 as compared to $43.7 million in the prior year quarter.
  • ET to review the fourth quarter and full year 2023 financial results and pipeline updates.

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Retrieved on: 
tisdag, februari 27, 2024
B cell, Therapy, Pharmacology, Diaphragm, Chemistry, Dystrophin, DMD, Part, Facial muscles, Duchenne muscular dystrophy, Exon, Conference, Wave, Health, Muscular Dystrophy Association, RNA, PN, Optimism, Protein, Oligonucleotide, RAPS, Half-life, MDA, Episcopal conference, Dietary supplement

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced its upcoming presentations at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 3-6 in Orlando, FL.

Key Points: 
  • Wave’s poster presentations will highlight the best-in-class potential of WVE-N531 in Duchenne muscular dystrophy (DMD), which is currently being evaluated in the Phase 2, potentially registrational FORWARD-53 study.
  • The presentations will also illustrate the impact of Wave’s novel PN chemistry on pharmacology of its exon skipping oligonucleotides.
  • These data suggest that WVE-N531 muscle concentrations in the clinic may be higher in heart and diaphragm than in skeletal muscle.
  • “At Wave, we increasingly continue to regard exon skipping as the preferred mechanism for altering DMD disease progression in those amenable to this approach.

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Retrieved on: 
tisdag, mars 5, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Genetics, Health Technology, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Other Science, Twist Bioscience, Twist, Reagent, Silicon, IVDR, NGS, Documentation, Doctor of Philosophy, Safety, Certification, Exon, Genome, Laboratory, DNA, IVD, Workflow, Medical device

The suite of our CE-marked Products includes:

Key Points: 
  • The suite of our CE-marked Products includes:
    The Twist Precision Prep and Enrichment Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic2
    Twist Precision Exome Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)
    The Twist Precision Prep and Enrichment Dx Kit and the Twist Precision Exome Dx Panel can be used individually within existing workflows or as a combined solution known as the Twist Precision Exome Dx Kit.
  • “The Twist Precision Dx products are our first NGS product line specifically developed to be included within regulated customer products.
  • The Twist Precision Exome Dx Panel1 is a qualified Twist DNA panel that can be used in conjunction with the Twist Precision Prep and Enrichment Dx kit to produce exome-enriched libraries compatible for NGS applications.
  • Twist Precision Exome Dx Kit1 utilizes the qualified Twist Precision Exome Dx Panel along with the Twist Precision Prep and Enrichment Dx Kit to produce exome-enriched libraries compatible for NGS applications.

Whole Genome Sequencing Market Global Industry Forecast Report 2018-2028, Featuring Profiles of Illumina, Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics & Veritas Genetics

Retrieved on: 
onsdag, januari 31, 2024
Cloud, Volcanic explosivity index, Whole genome sequencing, Growth, Microbiology, Workflow, WES, Genomics, Research, AI, DNA, Bacteria, Government, Gene, Mutation, Diagnosis, Microorganism, Exon, Competition, Exome sequencing, Sequence, Next Generation, NGS, Cloud computing, Cancer, Genome, Infection, Antibiotics

DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Whole Genome Sequencing Market is expected to grow with an impressive CAGR in the forecast period 2024-2028.
  • Increasing technological advancement in NGS instruments and update in technology utilized in Sequencing techniques are adding to further drive the sequencing market growth in the forecast period.
  • In this report, Whole Genome Sequencing Market has been segmented into the following categories:

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

Retrieved on: 
fredag, januari 5, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Patient, Gastrointestinal stromal tumor, Survival, Risk, Neoplasm, INSIGHT, Progression-free survival, Disease, KIT, DNA, Cancer, Liquid biopsy, Exon, Death, Nature Medicine, Manuscript, Overalls, PFS, Sunitinib, AP, GIST, Pharmaceutical industry

“The results published in Nature Medicine provide compelling evidence that QINLOCK may provide progression-free and overall survival benefit to second-line (2L) GIST patients in whom a liquid biopsy reveals primary KIT exon 11 mutations plus secondary mutations restricted to KIT exons 17 and 18.

Key Points: 
  • “The results published in Nature Medicine provide compelling evidence that QINLOCK may provide progression-free and overall survival benefit to second-line (2L) GIST patients in whom a liquid biopsy reveals primary KIT exon 11 mutations plus secondary mutations restricted to KIT exons 17 and 18.
  • “Our ongoing INSIGHT pivotal Phase 3 study is designed to confirm the exceptional efficacy we observed in this exploratory analysis from INTRIGUE.
  • A prespecified exploratory objective in INTRIGUE was to evaluate anti-tumor efficacy of QINLOCK according to baseline KIT primary and secondary mutation status.
  • In patients with a detectable KIT exon 11 primary mutation (n=157), 52 patients also had mutations in KIT exon 17/18 only and 41 had mutations in KIT exon 13/14 only.

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
tisdag, november 14, 2023
Trigger, Annual general meeting, Chemistry, Patient, Small RNA, Exosome, PLOS, Kidney, Webcast, Therapy, Exon, Business, MUSCULAR, Employment, Food, International, PUL, LVEF, RRM2, Ovarian cancer, Duchenne muscular dystrophy, MRI, Horizon, Commercialization, Amgen, WMS, ID, AAEV, BLA, Cohort, Vaccine, Tissue, Distribution deal, PPMD, Asos, Partnership, Biologics license application, DMD, Apoptosis, Distribution, Liver, Protein, Biotechnology, Cohort study, Mouse, Poster, Omicron, FDA, Seminal vesicles, File, CMC, HIV disease progression rates, Dietary supplement, Mobile phone, Pharmaceutical industry, Fine chemical, Video game, Nursing

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Next steps for Cohort A:
    Plan to report the outcome from the interim futility analysis in the fourth quarter of 2023.
  • Held a positive Type-B clinical meeting with FDA in the third quarter of 2023.
  • Next steps for Cohort B:
    Expect to commence enrollment for Cohort B in the fourth quarter of 2023.
  • Revenues for the third quarter of 2023 were approximately $6.2 million compared with approximately $1.6 million for the third quarter of 2022.